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Abstract
Background: Immunotherapy by using non-specific vaccines has 
proven to be effective in experimental animal models and also in 
patients suffering cancer. In the present work, the effectiveness of 
this immunotherapy was evaluated using a murine breast cancer 
model and a polymicrobial vaccine.
Methodology/Principal: Mice bearing injected with tumor cells 
from the spontaneous syngeneic mammary adeno carcinoma M3 
were used as breast cancer model. The immune adjuvant effect 
of the vaccine was analyzed in comparison or in the presence of 
doxorubicin. Tumor volume was calculated. Tumor, spleen and 
lymph nodes were processed for histological observations and to 
determinate the percentage of CD11c (+) cells.
Results: Mice treated with the vaccine or with doxorubicin 
decreased tumor growth, with less tumor cell invasion. Tumor 
tissues showed decreased necrosis and nuclear areas in mice 
that received any of the treatments under study, compared with 
the control group. The benefits of vaccination were associated to 
stimulation of the immune response. More hyperplasia of the red 
and white pulp, and increased marginal megakaryocytes were 
observed in the spleens from mice treated with the vaccine. CD11c 
(+) cells did not increase in tumor draining nodes by the immune 
stimulating effect of the vaccine; however, this treatment increased 
CD11c (+) cells in the spleen and tumor.
Conclusions: A non-specific vaccine used as immunotherapy 
can be used to prolong an equilibrium phase in the tumor growth, 
similar to the doxorubicin treatment used in the model, although 
by different mechanisms. Non synergic effect was observed in the 
group treated with both vaccine and doxorubicin (low dose). Future 
studies should be necessary to evaluate the correct combination 
of vaccination and cytotoxic drug can be used for this purpose and 
to achieve increased activated dendritic cells in the tumor draining 
lymph nodes.
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Introduction
Cancer is still one of the most common causes of mortality and 
morbidity throughout the world [1]. The possibilities of successful 
treatments accompanied or not by recurrence depend of the tumor 
type and the time of tumor growth in which it was discovered. The 
main treatments for cancer are surgery, chemotherapeutic agents 
and ionizing radiation to kill the tumor mass. These therapies have 
provided great benefits; however, the incidence of tumor recurrence 
is a major problem resulting from the development of mechanisms 
of resistance against the drugs and/or radiation by a portion of the 
tumor cells. This has led to the search for additional therapies that 
cause less secondary effects. One such strategy is the use of treatments 
designed to take advantage of the specificity of the immune system to 
recognize and kill tumor cells.
The concept that the immune system can respond against tumor 
development is now well recognized [2]. Data from animal models, 
together with data from human patients, indicate that the immune 
system is critical in the detection and eradication of tumor. Patients 
with congenital or acquired immunodeficiency, as well as patients 
undergoing immunosuppressive therapies have higher incidence of 
tumors compared to immuno competent individuals [3]. However, 
it is important to highlight that radiotherapy and chemotherapy, 
well established treatments of choice against cancer, are highly 
immunosuppressive.
A better understanding of the molecular interactions between 
tumors and the host immune system is essential for the development 
of new approaches for the simultaneous control of tumor escape routes 
and activation of antitumor immune responses. The combination of 
chemotherapeutic drugs in addition to immunotherapy with non-
specific anti-tumor vaccines can cause a beneficial immune response 
and increase the effectiveness of vaccines [4]. There are studies that 
have shown that non-specific vaccines can act to stimulate the host 
immune response against tumors, being William Coley the first 
who successfully used this methodology [5]. Since the descriptions 
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by Coley, different bacterial agents have been evaluated as immune 
adjuvants. Non-specific immune stimulation using Bacillus Calmette-
Guerin (BCG) was reported [6], especially against bladder cancer 
[7]. The vaccine was injected into the bladder through a catheter 
and BCG attracted the host’s immune cells to the bladder in order 
to attack the cancer cells. However, recent reports have shown the 
possibility (although low) of widespread BCG infection following 
intra vesicle treatment, and the need for vigilance in patients with any 
susceptibility or long term use of high doses of BCG [8-10].
Following this tendency to stimulate non-specifically the host 
immune system to attack cancer cells, the aim of the present work 
was to evaluate the immunotherapeutic effect of a polymicrobial 
vaccine, combined with cytostatic agents, using a scheme of multiple 
vaccinations in a murine breast cancer model. The chemotherapy and 
immune stimulating treatment were administered after tumor cell 
inoculation, determining its effectiveness by measuring tumor volume 
and its impact on the immune system by studying the histological 
architecture of the lymphoid organs and infiltrating dendritic cells in 
the tumor, lymph nodes and spleen.
Material and Methods
Animals and tumour induction
Six-week-old female BALB/c mice weighing 22 ± 2 g were 
obtained from the random-bred colony maintained at Facultad 
de Medicina, Universidad Nacional de Tucuman (San Miguel 
de Tucumán, Argentina). The spontaneous syngeneic mammary 
adenocarcinoma M3 was acquired from the Instituto de Oncología 
A.H. Roffo, Universidad de Buenos Aires (Buenos Aires, Argentina), 
which previously characterized it [11]. The tumor line was maintained 
by in vivo passage of the tumor cells to six syngeneic female mice 
every 15 days.
For the assay, one tumor was removed aseptically by surgery 
and placed into a sterile tube containing RPMI-1640 medium 
(Sigma, St Louis, MO, USA). It was then disaggregated mechanically 
with scissors and exposed to enzyme digestion. All enzymes were 
purchased from Sigma (St Louis, MO, USA). Tumours pieces were 
digested with protease (Pronase E) 0.05% for 15 min at 37 °C, stirring 
slightly with a magnetic agitator. The cell suspension was then 
washed with RPMI-1640 and treated with DNase 0.001% followed by 
centrifugation at low speed (800 g) to harvest the tumour cells. The 
pellet was suspended with RPMI 1640 containing 10% foetal bovine 
serum (FBS), and the concentration of cells was adjusted at 2 ± 1 × 106 
cell/ml, by counting in a Neubauer chamber with a solution of trypan 
blue (to take into account only the number of living cells). Each mouse 
was injected with 100 µl of this cell suspension (approximately 1 × 105 
cells per mouse) subcutaneously in the lower right mammary gland.
All animals received balanced chow diet ad libitum and were 
maintained in a room with a 12 h light/dark cycle at 18 ± 2 °C. 
All experiments comply with the current laws of Argentina. All 
procedures performed with animals were performed according to 
bioethical standards established for handling (regulation 6344/96, 
National Administration of Drugs, Food and Medical Technology 
-ANMAT) on requirements for animal facilities.
Vaccine and cytostatic agent
The vaccine used was Vacuna Liofilizada Casasco® (Casasco 
Laboratory, Buenos Aires, Argentina) which is purchased lyophilized 
in 5 vials, each one with increasing amounts of microorganisms 
(Table 1). The content of each vial was resuspended in 1ml of diluents 
(thimerosal 0.8 mg and distilled water, provided with the vaccine).
The vaccine is indicated for prophylaxis of ENT (ear, nose and throat 
- respiratory) and broncho pulmonary infections. It also contains 
glycolipid from Escherichia coli that increases circulating properdin 
(nonspecific immunity) for more than 7 days. Doxorubicin (Doxocris, 
Laboratory Kampel Martian S.A., Buenos Aires Argentina) was used 
as cytostatic agent.
Experimental protocol and measurement of tumor growth
Twenty eight mice were injected with the tumor cells as was 
explained above and divided into 4 groups (7 mice per group): Mice 
without treatment (Control group); mice treated with the vaccine 
(Vaccine group); mice treated with the cytostatic agent (Doxo group), 
and mice treated with both the vaccine and the cytostatic agent 
(Vaccine-Doxo group).
For the mice in the Vaccine group, the vaccine (vial 1) was 
injected intramuscularly (0.1 ml) 3 days after the inoculation of 
tumor cells. This treatment was followed by 4 injections of 0.1 ml each 
(days 6, 9, 13 and 17 post tumor cells) with increasing amounts of 
microorganisms using the vials 2, 3, 4 and 5, respectively.
For Doxo group, doxorubicin treatment consisted of 2 
intravenous injections (in the tail vein) of 0.1 ml that contained 150 
µg of the drug. The injections were performed 3 and 14 days post 
inoculation of tumor cells.
For Vaccine-Doxo group, a lower dose of doxorubicin (30 µg) 
was used following the same protocol of 2 injections described 
above. The vaccination was similar to the Vaccine group, but the 
first injection was 4 days after the inoculation of tumour cells and the 
other injections were on days 7, 11, 17 (4 injections in total, without 
the vaccine from vial N °5). The first application of the vaccine was 
one day after doxorubicin (day 4), and the last inoculation was 6 
days after the 3rd one because the second doxorubicin injection was 
between 3rd and 4th vaccine injection). This protocol was followed to 
ensure a lower concentration of this cytostatic drug in circulation, 
and in this sense to diminish the effect of the drug in the clonal 
expansion and the activation of the immune cells at the time of the 
immune stimulation.
Tumor growth was evaluated by caliper measurement of the tumor 
length and width 3 times per week. Tumor volume was calculated 
using the formula V = (d2 × D) / 2, where V is the volume in mm3, and 
d and D are the shortest and longest diameters, respectively.
Sampling procedure
Samples were obtained 21 days after tumor cell injection. All mice 
were sacrificed by cervical dislocation. Four mice per group were used 
to obtain samples of tumor, spleen and lymph nodes (inguinal lymph 
nodes on both sides) for flow cytometry analyses, and three mice per 
group to obtain the same samples for optical microscopy.
Histological analysis
Tumors and spleen were examined macroscopically and then 
fixed with buffered formalin solution and embedded in paraffin. 
Tissue sections (4 µm) were stained with hematoxylin-eosin.
For the analysis of spleens, the results were expressed with a semi-
quantitative score system. One (+), two (++) or three (+++) crosses 
refer to mild, moderate or severe hyperplasia in the red or white 
pulp, respectively. Similarly, for megakaryocytes, their marginal 
distributions were semi-quantified by considering one, two and three 
crosses for mild, moderate and severe increases, respectively.
For the tumors, histomorphometric determinations were 
performed on digitized photomicrographs of histological slides 
Table 1: Vaccine composition.
Microorganism# Vial N°1 Vial N°2 Vial N°3 Vial N°4 Vial N°5
Streptococcus pneumoniae 100 200 300 400 600
Haemophilus influenza 50 100 150 200 300
Klebsiella pneumoniae 50 100 150 200 300
Micrococcus sp. (respiratory) 50 100 150 200 200
Branhamellacatarrhalis 50 150 150 200 200
Streptococcus sp. (respiratory) 100 300 300 400 400
Excipients†
Povidone 8.0 8.0 8.0 8.0 8.0
Sodium chloride 8.5 8.5 8.5 8.5 8.5
Mannitol 50.0 50.0 50.0 50.0 50.0
#The count of microorganisms in each vial is expressed × 106.
†The concentration of excipients in each vial is expressed in mg.
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using Image Proplus 4.5 Software. The parameters evaluated were: 
1) Tumor necrosis area: Area total of necrosis and tumor necrosis 
per field (as observed at 100X). Measurements were performed on 
5 randomly selected microscopic fields of tumor tissue. The criteria 
taken into account to measure areas were basophilic granular area 
excluding optically empty areas. 2) Number of mitosis: Ten randomly 
selected microscopic fields of tumor tissue were examined at 400X. 
The different mitosis phases (prophase, metaphase, anaphase and 
telophase) were considered. 3) Nuclear area: Ten randomly selected 
microscopic fields of tumor tissue (observed at 400X) were evaluated 
to measure the nuclear area of 30 randomly selected nuclei.
Determination of CD11c (+) cells by flow cytometry
Lymph nodes, spleen and tumors were collected, and 
mechanically disintegrated. For tumor samples this step was followed 
by an enzymatic digestion as was described above. Cell concentration 
was adjusted at 2 ± 1 x 106 cells/ml. Isolated cells were incubated in 
darkness with the monoclonal FITC hamster anti-mouse CD11c 
antibody (BD Bioscience, San Diego, USA). Labeled cells were 
analysed with a FACS Partec Pas Cytometer (BD Bioscience, San 
Diego, CA, USA) equipped with Flomax software.
Statistical analysis
The design was a case-control study and the variables were studied 
qualitative and quantitatively. Sigma Stat V2.0 and SPSS v.15.0 were 
used. The comparisons were accomplished by an ANOVA general 
linear model followed by a Tukey’s post-hoc test.
Results
Effect of vaccination and doxorubicin treatment on tumor 
growth
Tumor volume from mice of Vaccine group and Doxo group 
showed a statistically significant decrease (P < 0.05) compared to the 
control group, at day 18. After 21 days, the Vaccine group showed 
an average decrease of 47% in tumor volume, and Doxo group 42% 
(P < 0.001), compared to the control animals. For the Vaccine-Doxo 
group no significant differences were observed when compared to the 
control group (P = 0.182) (Figure 1); similarly, the treatment with low 
dose of doxorubicin (30 µg) was not associated to significant changes 
compared to control group (data not shown).
Histopathological modifications associated to vaccination 
and doxorubicin treatment in tumor bearing mice
The analysis of spleens showed different levels of hyperplasia in 
the white and red pulp in the samples obtained from the different 
groups. In the control group, 67% of the samples showed moderate 
hyperplasia of the red and white pulp (Table 2). For marginal 
megakaryocytes, the 33% showed a slight amount, 33% moderate and 
the other 33% severe amount (Table 2). The analysis of hyperplasia of 
red pulp in the different test groups showed the 100% of the samples 
with moderate hyperplasia. For the white pulp, the observations 
were different in the samples from the 3 test groups. For Vaccine 
group, 67% of the samples had moderate hyperplasia, for Doxo 
group the 100% of the samples showed slight hyperplasia, and for 
Vaccine-Doxo group, it was observed the same percentage (33.3%) of 
samples with each score (Table 2). Finally, the evaluation of marginal 
megakaryocytes showed moderate amounts in the highest percentage 
of samples obtained from the 3 test groups (Table 2).
Microscopic appearance of adenocarcinoma M3 was analysed 
in control and test groups. For the control group all the samples 
presented adipocyte tissue and angio lymphatic invasion, and 67% of 
mice showed muscle and perivascular invasion (Table 3). This group 
also showed a high percentage (67%) of severe tumor necrosis (Figure 2). 
The results obtained in the Vaccine and Doxo groups were similar, 
without perineural and angio lymphatic invasion, and with 100% of 
the samples showing perivascular invasion. However, in the Vaccine 
group, invasion of muscle tissue was observed, and for Doxo group 
the adipocyte tissue was invaded (Table 3). In the Vaccine-Doxo 
group predominance of adipocyte tissue, muscle and perivascular 
invasions were observed (Table 3).
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Figure 1: Rate of tumor growth. Results are expressed as the average of the tumor volume (mm3) for each group. Each group consisted of 7 mice. Statistical 
analysis is show for the last measurement. Means values without a common letter differ significantly (P < 0.05).
Table 2: Hyperplasia and marginal megakaryocytosis in spleen.
Control# Vaccine# Doxo# Vaccine-Doxo#
Red pulp† +
++
+++
33%
67%
0%
0%
100%
0%
0%
100%
0%
0%
100%
0%
White pulp† +
++
+++
67%
33%
0%
33%
67%
0%
100%
0%
0%
33%
33%
33%
Marginal 
megakaryocyte††
+
++
+++
33%
33%
33%
0%
100%
0%
0%
67%
33%
33%
67%
0%
#Each column shows the percentage of mice from each group that presented de 
degree of histological alterations.
†Hyperplasia of red and white pulp was qualitatively evaluated as slight (+), 
moderate (++) or severe (+++).
††The presence of marginal megakaryocytes was qualitatively expressed as 
slight (+), moderate (++) or severe (+++).
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Discussion
The immune system is prepared to identify and specifically kill 
tumor cells, based on the expression of specific tumor antigens or 
certain molecules induced during tumor development [12]. However, 
although effector cells are present, they are often ineffective in vivo, 
and the tumor continues to grow and the metastasis can invade 
different organs. The sentinel lymph node is where the potentially 
auto-reactive lymphocytes encounter antigens and develop acquired 
immunity. The down-regulation of immune activity in the lymph 
nodes near the primary tumors indicates that sentinel nodes are 
more immuno modulated than the regional distant lymph nodes 
[13]. Also, it is known that immuno suppression is accentuated with 
chemotherapy treatments based on actively proliferating cell killing 
since immune cells are in this category, when activated,  induce a 
response against foreign antigens [14].
These observations have led to the design of new therapeutic 
approaches for cancer. Traditional vaccines induce immunity to certain 
microbial antigens and prevent infectious diseases. Immunotherapy 
has proven to be effective in experimental animal tumor models and 
also in patients suffering cancer (as was described in the introduction 
of this article), with the Mycobacterium bovis BCG vaccine strain 
the most used. In the present work, the effectiveness of non-specific 
anti-tumor immunotherapy was demonstrated using a breast cancer 
The histo metric analysis of the tumors is shown in (Figure 2). 
A significant decrease (P < 0.001) in tumor necrosis area was 
observed with all the assayed treatments compared to the control 
group (Figure 2A). No significant differences between the control 
group and the test groups were observed for the mitosis index 
(Figure 2B). In contrast, a significant decrease (P < 0.05) of nuclear 
area was observed when the test groups were compared with the 
control. All treatments decreased the nuclear area, with the largest 
diminution observed in the Vaccine-Doxo group (average of 25.5% 
compared to the control (Figure 2C).
Evaluation of dendritic cells
The percentage of CD11c (+) cells in spleen showed a significant 
increase (P < 0.001) in the Vaccine group, compared to the control 
group. A lower, but also significant increase (P < 0.05) was observed 
in the Vaccine-Doxo group, compared to the control. No significant 
differences between the control group and the Doxo group (P = 
0.150) were observed (Figure 3).
Lymph node did not show significant differences for the percentage 
of CD11c (+) between the control and test groups (Figure 3).
For tumor samples, even with large variation of data, the Vaccine 
group was the only one that showed a significant increase (P < 0.05) in the 
percentage of CD11c (+) cells compared to the control group (Figure 3).
Table 3: Invasion of neoplastic cells.
Adipocyte tissue Muscle tissue Perivascular Perineural Angiolymphatic
Abs Pres Abs Pres Abs Pres Abs Pres Abs Pres
Control 0 3 1 2 1 2 2 1 0 3             
Vaccine 3 0 0 3 0 3 3 0 3 0      
Doxo 0 3 3 0 0 3 3 0 3 0
Vaccine-Doxo 0 3 0 3 2 1 3 0 3 0
Each column shows the number of mice from each group (total N = 3) with or without the evaluated invasion. Abs and Pres mean absence and presence, respectively.
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Figure 2: Histological evaluations of the tumors. Figure A shows the analysis of necrosis. The percentage of animals with slight, moderate or severe necrosis is 
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compared to the Control group are represented with asterisk (*).
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A decrease in density of the DC in the sentinel node and in 
the para cortex area occupied by DC was observed in several solid 
tumors, such as in melanoma and breast cancer [18,19]. However, 
it is not clear whether the decreased density of DC in the sentinel 
node is due to a decreased flow of carriers DC antigen, or possibly 
to an increase in apoptosis of DC after interaction with T cells in the 
sentinel node [20].
CD11c is generally expressed by DC and it was used to analyse 
these cells in our model; however, this surface marker can express 
on other myeloid cells, lymphocytes and natural killer cells. The 
analysis of CD11c (+) cells showed that although the number was not 
increased in tumor draining nodes by the immune stimulating effect 
of the vaccine, this treatment increased the number of CD11c (+) cells 
in the spleen and tumor. This effect was related with decreased tumor 
volume in the vaccine-treated groups compared to the control group. 
In contrast, in the group treated with doxorubicin this correlation 
was not observed: the mice showed similar percentage of CD11c (+) 
cells in spleen and tumor than the ones of the control group. In these 
animals, the decrease of tumor volume would be due to the cytotoxic 
effect of the drug. Finally, in the group treated with both doxorubicin 
and vaccine, the tumor volume remained unchanged compared to 
the control although the percentage of CD11c (+) cells increased. 
These results indicate that there is not a synergistic anti-tumor effect 
between doxorubicin and the vaccine in the conditions assayed. 
The dose of doxurubicin(less than the one used in the group only 
treated with the cytotoxic agent) was not enough to affect the tumor 
growth, and even highlighting the positivity of increased CD11c (+) 
cells, probably the low doses of cytotoxic therapy affected induction 
or effector pathways of anti-tumor immune response. DC or other 
immune cells (T helper lympocytes, cytotoxic lymphocytes, natural 
killer, Treg lymphocytes, among other) could be affected by the drug, 
and the correct immune response was not driven.
Our finding show that a non-specific vaccine used as 
immunotherapy prolonged an equilibrium phase in the tumor growth, 
similar to the doxorubicin treatment used in the model, although 
by different mechanisms. In this model, we did not observe tumor 
regression with the treatments assayed and future studies should be 
necessary by modifying the dose and/or type of cytotoxic drug to 
evaluate if a correct combination of vaccination and cytotoxic drug 
can be used for this purpose and to achieve increased activated DC in 
the tumor draining lymph nodes. The analysis of other cell markers, 
in addition to CD11c, will allow understanding the importance of 
DC or other immune cells in the beneficial effects obtained with the 
vaccination in our breast cancer model.
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model in mice and a polymicrobial vaccine. Mice treated with the 
vaccine decreased tumor volume, similar to the animals treated with a 
cytostatic drug. These benefits were associated to histo morphometric 
modifications in the tumor tissues. The lower beneficial effects of the 
vaccine observed in the group that received it with the doxorubicin 
can be attributed to the immune suppressed effect of the drug, which 
interacts with the immune stimulation associated to the vaccine. The 
results obtained in the assayed model showed that when applied at 
the nearly same time with vaccinations, low dose of doxorubicin was 
capable of abrogating vaccine-mediated immune modulatory and 
antitumor effects, which was observed principally in the analysis of 
tumor volume. It is also important to note that the low dose of this 
chemotherapeutic drug was not associated to significant benefits 
compared to control group (data not shown).
The participation of immune cells in the response against the 
tumor was also evaluated at different levels. In the spleen, the vaccine 
group was the one that showed the highest hyperplasia of red and 
white pulp, and increased the marginal megakaryocytes. The benefit 
associated to this treatment was also analysed with the evaluation of 
invasion by tumor cells. This was similar in both vaccine and Doxo 
groups, and lower than in the control group. In addition, severe 
necrosis was not observed in the treated animals.
The presence of immune modulatory cytokines is an important 
aspect of the complex immune response to infection, and it has also a 
significant role in reducing tumor growth by non-specific vaccination, 
as was recently demonstrated for the intravesical administration of 
BCG in the treatment of bladder cancer [15]. Several cytokines have 
been detected in urine of the patients, such as IL-2, IL-8, IL-6, IL-
1ra, IL-10, IL-12[p70], IL-12[p40], TRAIL, and TNF-α, and they 
can be used to predict the probability of tumor recurrence. These 
cytokines can be produced by the stimulated immune cells and 
some of them directly by the tumor cells. In this context, the study 
of dendritic cells (DC) has been gaining interest against cancer and 
they have also been evaluated in our experimental model. DC have a 
central role in developing specific immune response against different 
antigens an also in antitumor responses [16,17]. Two therapeutic 
approaches have been proven: the stimulation of in vivo development 
of protective immunity or by providing the patient with effector cells 
grown in vitro.
In the present work, we tried to stimulate in vivo an anti-
tumor response and, in the respective model, to revert the immune 
suppression caused by chemotherapy, based on the cytokines induced 
by vaccination. The cytokines generated in the primary response and 
with re-stimulations (secondary response) could help in capturing 
the tumor antigens by the DC and promote antigen presentation and 
the development of specific immune response against the tumor.
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